ABBVIE INC. CALLS STOCKHOLDERS MEETING
Texte intégral
(2)
Documents relatifs
Important Additional Information This press release does not constitute an offer to purchase, or a solicitation of an offer to sell, shares of common stock of Pharmacyclics, nor is it
Important Additional Information This press release does not constitute an offer to purchase, or a solicitation of an offer to sell, shares of common stock of Pharmacyclics, nor is it
AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section
AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section
THE TENDER OFFER MATERIALS INCLUDING AN OFFER TO EXCHANGE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS AND THE SOLICITATION/RECOMMENDATION STATEMENT
The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most
As reported GAAP Adjusted for specified items: Intangible asset amortization Separation costs R&D Acquired IPR&D Calico collaboration Shire transaction costs Other As
These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie's experience and perception of historical trends, current conditions,